17 results about "Integrin receptors" patented technology

The invention relates to the technical field of biological medicines, in particular to an iRGD targeted and anti-fibrosis small molecule dual-modified exosome as well as a construction method and application thereof. The exosome utilizes the specific binding penetration enhancement effect of iRGD (the amino acid sequence is CRGDKGPDC) and a fibroblast high-expression integrin receptor, so that the enrichment efficiency of the exosome at a focus part is improved; the anti-fibrosis micromolecule Let-7a-5p can inhibit a TGF-beta signal channel by blocking Smad2 / 3 phosphorylation, and the anti-fibrosis micromolecule Let-7a-5p and the anti-fibrosis microRNA carried by the exosome generate a synergistic anti-fibrosis effect; the exosome phospholipid bilayer can also protect Let-7a-5p from enzymolysis and prolong the half-life period, and iRGD modification can reduce the non-targeted uptake rate. An animal model verifies that the double-modified exosome has a good skin fibrosis resisting effect, and side effects such as liver and kidney function damage are not found. The invention provides an effective and safe treatment scheme for resisting skin fibrosis.

The invention belongs to the technical field of mesenchymal stem cell exosome compositions, and discloses a preparation method and application of a mesenchymal stem cell exosome composition. The mesenchymal stem cell exosome composition is prepared from a mesenchymal stem cell exosome, a hyaluronic acid-arginine grafted copolymer, acetyl tetrapeptide-5, resveratrol, mannose, polyglycerol-8 octoate and a buffer solution. Arginine residues contained in the hyaluronic acid-arginine graft copolymer in the composition can be specifically combined with integrin receptors (such as alpha v beta 3) highly expressed by fibroblasts at the wrinkle part, so that the exosome can actively anchor the wrinkle part, can be accurately and directionally enriched at the wrinkle part, and is high in utilization rate and high in anti-wrinkle efficiency. The composition constructs a three-dimensional anti-wrinkle network of mesenchymal stem cell exosome, acetyl tetrapeptide-5 and resveratrol, skin collagen degradation and oxidative damage are effectively restrained, and generation of skin wrinkles is blocked through multiple channels.

This patent discloses a dual targeting lipid-based formulation designed for precise drug delivery to the thyroid gland, addressing the complexities of thyroid disorders. The formulation integrates two key technologies: the RGDFK Targeting Motif and Iodine Coupling. The RGDFK motif enhances specific binding to αvβ3 integrin receptors, facilitating internalization of therapeutic agents. Simultaneously, the Iodine Coupling technology leverages the thyroid gland's natural affinity for iodine, ensuring increased accumulation of lipid-based vesicles in thyroid tissue. Applications of this formulation extend to targeted treatment of diverse thyroid disorders, symptom-specific relief, and nutritional supplementation. The formulation serves as a fundamental component in pharmaceutical compositions, adaptable for various administration routes. The manufacturing process emphasizes scalability, reproducibility, and standardized quality. A comprehensive treatment kit has been devised, offering a convenient and tailored approach to thyroid drug delivery. In conclusion, this dual targeting lipid-based formulation signifies a paradigm shift in thyroid disorder therapeutics, promising precision, efficacy, and patient-centric care. As it advances towards clinical applications, it holds the potential to redefine the landscape of thyroid health management for enhanced patient outcomes.

This invention provides a linear polypeptide and its application in cosmetics, belonging to the field of active molecule development technology. The polypeptide provided by this invention has a higher binding affinity to integrin receptors, significantly promoting fibroblast proliferation, increasing the content of elastin and type III collagen in the skin, and effectively scavenging DPPH free radicals and reducing reactive oxygen species levels. This polypeptide can be widely used in the preparation of cosmetics or topical skin formulations with anti-aging, antioxidant, and skin-repair promoting functions. It features high activity, good stability, and excellent safety, making it suitable as an active ingredient in functional skincare products.

The present invention belongs to a biopharmaceutical technology, and specifically relates to a fusion polypeptide and a derivative thereof, and the use thereof in the preparation of a drug for treating alopecia, acne, dermatitis and other related diseases. Disclosed is a fusion polypeptide, wherein the fusion polypeptide sequentially consists of an O peptide or a derivative peptide thereof, and an I peptide or a derivative peptide thereof from the N-terminus to the C-terminus, and the two structural functional domains are connected via a linker peptide linker or directly; or the fusion polypeptide sequentially consists of an I peptide or a derivative peptide thereof, and an O peptide or a derivative peptide thereof from the N-terminus to the C-terminus, and the two structural functional domains are directly connected via a linker peptide. The provided fusion polypeptide can simultaneously activate GPR158 and / or GPRC6A and / or GPR37 pathways, and simultaneously activate the integrin receptor pathway, has the remarkable advantages of high activity in promoting hair growth, rapid onset of action and long action duration in regulating hormone, thereby providing a new drug for treating alopecia, acne, dermatitis and other related diseases.

The embodiment of the invention discloses recombinant XVII humanized collagen and a preparation method thereof, relates to the technical field of recombinant protein, and aims to solve the technical problem of low preparation efficiency of existing XVII type collagen. The preparation method of the recombinant XVII humanized collagen comprises the following steps: obtaining an amino acid sequence containing an integrin receptor site "RGD" and a binding site "KGHK"; based on the amino acid sequence, obtaining recombinant humanized collagen protein granules; the method comprises the following steps: obtaining recombinant lysine hydroxylase gene plasmids on the basis of a human gene LH2; and obtaining the recombinant XVII humanized collagen on the basis of the recombinant humanized collagen protein plasmid and the recombinant lysine hydroxylase gene plasmid.

The invention discloses a small molecule peptide with cytotoxicity to breast cancer cells and application, and relates to the technical field of establishment and preparation of a small molecule peptide nano-drug delivery system. The small molecule peptide is a targeted peptide modified alkaline phosphatase reaction peptide, responds to ALP enzyme, is specifically combined with an integrin receptor, is self-assembled into spherical nanoparticles and serves as a nano drug carrier, and the structural formula is shown in figure 1. The research successfully designs and synthesizes a small molecule peptide with cytotoxicity to breast cancer cells, the small molecule peptide can be self-assembled into a nano NP drug delivery system, and an in-vitro experiment result shows that the self-assembled nano NP drug delivery system can quickly release chemotherapeutic drugs in an ALP overexpression environment, has small damage to healthy cells, is relatively low in cytotoxicity, and can be used for preparing a chemotherapeutic drug for treating breast cancer. However, the damage to cancer cells is obvious, and the action time of the medicine can be prolonged. An in-vivo anti-tumor experiment shows that compared with a non-deformable control peptide, the small molecule peptide drug loading system has a remarkable anti-tumor effect.

The invention discloses a polypeptide oligonucleotide coupling conjugate capable of being combined with an integrin alpha v beta 6 protein receptor, and further discloses a composition containing the oligonucleotide conjugate and application of the composition, and the conjugate can be used for preparing a medicine, a medicine, a medicine carrier and the like. The medicine can be used for preventing and / or treating diseases related to the medicine delivered through the mediation of the integrin receptor alpha v beta 6 protein receptor.

Provided are a recombinant human fibronectin (FN) having a complex function of soothing, a preparation method therefor, and the use thereof. Said recombinant human fibronectin has an amino acid sequence shown as SEQ ID NO.1. By adding a hyaluronic acid interaction segment of human fibronectin while retaining main segments of human fibronectin cell adhesion and integrin receptor interaction, and linking the two domains by means of a flexible "linker" amino acid sequence GGS, the recombinant human FN protein having the complex function is constructed. While possessing core characteristics of traditional recombinant fibronectins, the present recombinant human fibronectin also exhibits an effect of soothing cell irritations. Therefore, the prepared recombinant human fibronectin is expected to exhibit a good effect in soothing skin irritation in the field of functional active skincare products.

The application relates to an integrin receptor targeting polypeptide derivative and molecular probe and application. The integrin receptor targeting polypeptide derivative has a structure shown in formula I. The novel polypeptide derivative constructed by the application has the function of simultaneously coupling multiple imaging molecules, and can be simultaneously used for preoperative diagnosis and intraoperative guidance of multiple imaging methods. The research result can provide a new idea for further development of molecular imaging, and increase the range of clinical application of molecular imaging.

Described herein are conjugates targeting the ανβ6 integrin receptor and pharmaceutical compositions (e.g., radiopharmaceutical compositions) comprising said conjugates. The subject conjugates and compositions are useful for the treatment of a disease or disorder associated with ανβ6 integrin receptor. In some embodiments, a conjugate described herein has a structure of the following formula:, wherein values for the variables are as described herein.

The invention belongs to the field of biotechnology and pharmaceutical industry, and particularly relates to an RGD macrocyclic peptide multivalent antibody recruitment molecule specifically combined with integrin and application of the RGD macrocyclic peptide multivalent antibody recruitment molecule. The multivalent antibody recruitment molecule has an A-B-C structure, A is an antibody hapten structure, B is a connecting arm, and C is RGD cyclic peptide. The multivalent DNP structure is synthesized by using lysine as a skeleton molecule, and then RGD macrocyclic peptide is inoculated through an azide reaction catalyzed by copper ions, so that the RGD macrocyclic peptide multivalent DNP antibody recruitment molecule capable of being combined with an integrin receptor is obtained. A flow cytometry experiment and a cytotoxicity experiment prove that the RGD macrocyclic peptide coupled multivalent DNP antibody recruitment molecule has a good capability of specifically selectively combining an alpha v beta 3 integrin receptor, and has a good toxic effect on tumor cells with relatively high expression abundance of the alpha v beta 3 integrin receptor; therefore, the molecules have potential value in the aspect of cancer targeted therapy.

The invention discloses an X-ray response type neutrophile granulocyte loaded nanometer vitepofen and an application thereof. According to the invention, a solvent-anti-solvent method is combined with a hydrothermal method to prepare the nano vitepofen. The nanometer vitepofen can adsorb part of protein in plasma in vivo, and a'protein crown 'layer is formed on the surfaces of particles. The adsorbed complement C3 can be specifically combined with a CR3 receptor on the surface of the activated neutrophil, and proteins such as fibrinogen and the like can be combined with an integrin receptor on the surface of the neutrophil, so that the nano vitepofen is delivered to a tumor focus in a targeted manner by utilizing the inflammatory chemotactic characteristic of the neutrophil. Moreover, the nano vitepofen has an X-ray response characteristic, and can generate active oxygen in tumor cells under X-ray irradiation and induce the tumor cells to generate immunogenic death, so that the anti-tumor immune response of an organism is triggered, the radiotherapy curative effect is enhanced, and the radiotherapy sensitization is realized.

The invention relates to a polypeptide coupling compound with high affinity to an integrin receptor (alpha V beta 3) and pharmaceutically acceptable salts thereof, a pharmaceutical composition containing the polypeptide coupling compound and the pharmaceutically acceptable salts, and application of the pharmaceutical coupling compound and the pharmaceutical composition in preparation of drugs for preventing and / or treating alpha V beta 3 overexpression diseases.

The invention provides a polypeptide supporting in-vitro culture of human pluripotent stem cells and application, and belongs to the technical field of regenerative medicine. The sequence of the polypeptide is KGGPQVTRGDTFRYI or KGGPQVTRGDTYHSY, and the sequence of the polypeptide is shown as KGGPQVTRGDTYHSY. The polypeptide provided by the invention has excellent cell adhesion capacity, enhances the interaction between cells and an integrin receptor alpha v beta 5, and significantly improves the efficiency and quality of human pluripotent stem cell culture. By using the polypeptide sequence provided by the invention, the dependence on animal source materials is reduced, the biological safety and compatibility of a culture system are improved, and more effective and safer support is provided for clinical application of hPSCs.

Provided herein are α4β1 / 7 integrin receptor ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility such as one or more small molecule integrin agonist adjuvants in a substantially non-aqueous carrier composition that comprises at least one phospholipid, at least one neutral lipid, and at least one pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g., orally, to a subject in need thereof.